University of Nebraska - Lincoln

DigitalCommons@University of Nebraska - Lincoln
Papers in Plant Pathology

Plant Pathology Department

5-1-1993

Evidence for Virus-Encoded Glycosylation Specificity
Ing-Nang Wang
University of Nebraska-Lincoln

Yu Li
University of Nebraska-Lincoln

Quideng Que
University of Nebraska-Lincoln

Meenakshi Bhattacharya
University of Nebraska-Lincoln

Leslie C. Lane
University of Nebraska-Lincoln, llane1@unl.edu
See next page for additional authors

Follow this and additional works at: https://digitalcommons.unl.edu/plantpathpapers
Part of the Plant Pathology Commons

Wang, Ing-Nang; Li, Yu; Que, Quideng; Bhattacharya, Meenakshi; Lane, Leslie C.; Chaney, William G.; and
Van Etten, James L., "Evidence for Virus-Encoded Glycosylation Specificity" (1993). Papers in Plant
Pathology. 156.
https://digitalcommons.unl.edu/plantpathpapers/156

This Article is brought to you for free and open access by the Plant Pathology Department at
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Papers in Plant Pathology by
an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.

Authors
Ing-Nang Wang, Yu Li, Quideng Que, Meenakshi Bhattacharya, Leslie C. Lane, William G. Chaney, and
James L. Van Etten

This article is available at DigitalCommons@University of Nebraska - Lincoln: https://digitalcommons.unl.edu/
plantpathpapers/156

Published in Proceedings of the National Academy of Sciences USA 90:9 (May 1, 1993), pp. 3840-3844. Copyright © 1993 National Academy of Sciences
USA. Used by permission. http://www.pnas.org/content/90/9/3840.full.pdf+html
Microbiology

Evidence for virus-encoded glycosylation specificity
(algal virus/chlorella/serotypes)
Ing-Nang Wang,1,3 Yu Li,1 Quideng Que,1 Meenakshi Bhattacharya,1 Leslie C. Lane,1 William G. Chaney,2 and James L. Van Etten 1
1 Department

of Plant Pathology, University of Nebraska–Lincoln, Lincoln, NE 68583-0722
of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198-4525
3 Present address: Department of Ecology and Evolution, State University of New York, Stony Brook, NY 11794
2 Department

Communicated for PNAS by Myron K. Brakke, January 11, 1993. Corresponding author — J. L. Van Etten

alga (Chlorella NC64A) on MBBM medium have been described (1, 8). Virus glycoproteins were specifically labeled by
adding 100 μCi of D-[6-3H]-galactose (1 Ci = 37 GBq) to 1 ml of
cells (6 x 108 cells per ml) 30 min after virus infection. After lysis, the labeled virions were isolated by standard procedures.
Isolation of PBCV-1 Serotypes. Spontaneous serotype
mutants of PBCV-1 or its relatives were isolated by incubating 1 x 109 plaque-forming units (pfu) of virus with virus polyclonal antiserum (1:10 dilution) for 30 min, removing agglutinated virus by centrifuging (3000 × g) for 5 min, and titering
the supernatant. Typically 500–1,000 antiserum-resistant viruses were obtained from 109 pfu of parent virus and >95% of
these plaques consisted of mutant viruses that were insensitive
to the original virus antiserum; i.e., <5% of the plaques were
from parent viruses that escaped antiserum precipitation.
Polyacrylamide Gel Electrophoresis of Virus Proteins and
Western Blot Analysis. Purified viruses [0.06 A260 unit in 10
μl of 50 mM Tris HCl (pH 7.8)] were mixed with 10 μl of 2×
dissociation buffer [125 mM Tris HCl, pH 8.4/3% (wt/vol)
SDS/20% (vol/vol) glycerol/0.1 M dithiothreitol/0.08% bromophenol blue] and heated to 65°C for 1 hr or 100°C for 5 min.
Samples were electrophoresed on a linear 6–18% polyacrylamide gradient slab gel with a 4% stacking gel at 70 V for 16 hr
in the buffer system of Laemmli (9). Proteins were visualized
by silver staining (10).
Proteins were transferred to nitrocellulose sheets at a constant current flux of 1 mA/cm2 for 5 hr at room temperature
in the buffer system described by Towbin et al. (11) with 20%
(vol/vol) methanol. The sheets were washed for 5 min in 1×
TBST buffer (10 mM Tris-HCl, pH 8.0/150 mM NaCl/0.05%
Tween 20) and incubated for 1 hr in TBST with 5% (wt/vol)
nonfat dry milk (blocking solution) containing primary antiserum diluted 1:750 to 1:1000. The sheets were washed three
times in TBST, incubated for 1 hr at room temperature with
goat anti-rabbit IgG-conjugated alkaline phosphatase (1:2000
dilution) in blocking solution, washed three times in TBST,
and incubated in alkaline phosphate (AP) buffer (100 mM TrisHCl, pH 9.5/100 mM NaCl/5 mM MgCl2) for 5 min. Color
was developed by incubating the sheets in 15 ml of AP buffer
containing 40 μl of nitroblue tetrazolium (112 mg dissolved in
1 ml of N,N-dimethyl formamide and 0.5 ml of water) and 32
μl of 5-bromo-4-chloro-3-indolyl phosphate (100 mg dissolved
in 2 ml of N,N-dimethyl formamide) (12). Color development
was stopped by placing the sheets in distilled water.
Isolation of Virus Major Capsid Protein. Viral glycoproteins,
including the major capsid protein Vp54, were dissociated from
virions by incubating purified virus in 50 mM Tris HCl (pH 7.8)
at 65°C for 1 hr and then centrifuging at 10,000 × g for 10 min.
At least 80% of the supernatant protein consisted of Vp54. The

Abstract: Four spontaneously derived serologically distinct classes of
mutants of the Paramecium bursaria chlorella virus (PBCV-1) were isolated using polydonal antiserum prepared against either intact PBCV-1
or PBCV-1-derived serotypes. The oligosaccharide(s) of the viral major
capsid protein and two minor glycoproteins determined virus serological specificity. Normally, viral glycoproteins arise from host-specific
glycosylation of viral proteins; the glycan portion can be altered only
by growing the virus on another host or by mutations in glycosylation
sites of the viral protein. Neither mechanism explains the changes in
the glycan(s) of the PBCV-1 major capsid protein because all of the viruses were grown in the same host alga and the predicted amino acid
sequence of the major capsid protein was identical in the PBCV-1 serotypes. PBCV-1 antiserum resistance is best explained by viral mutations that block specific steps in glycosylation, possibly by inactivating
glycosyltransferases.
Abbreviations: PBCV-1, Paramecium bursaria chlorella virus; TFMSA,
trifluoromethanesulfonic acid.

Paramecium bursaria chlorella virus (PBCV-1) is a large (≈190
nm in diameter) polyhedral plaque-forming virus that replicates in certain unicellular eukaryotic exsymbiotic Chlorellalike green algae (1). The PBCV-1 genome is a linear nonpermuted 333-kb double-stranded DNA with covalently closed
hairpin ends (2, 3). PBCV-1 contains at least 50 proteins and
a lipid component located inside the capsid shell (4). The major capsid protein (Vp54) of PBCV-1 is one of four proteins located on the viral surface and is one of three glycosylated viral proteins. PBCV-1 and its related viruses have recently been
assigned to a virus family, named Phycodnaviridae (5). Additional features of these viruses have been reviewed (6).
Chase et al. (7) showed that chlorella viruses exclude one
another during dual inoculation of the host. For these studies
we isolated a spontaneous mutant of PBCV-1, named EPA-1,
which was resistant to PBCV-1 polyclonal antiserum (dilution
of 1:4). This antiserum completely inhibited PBCV-1 infection
even at a dilution of 1:1000. Polyclonal antiserum prepared
against EPA-1 inhibited EPA-1 infection (dilution of 1:1000)
but not PBCV-1 infection (dilution of 1:4). In this study we
have addressed two questions: (i) Can additional PBCV-1 serotypes be isolated using polyclonal antisera to intact viruses?
(ii) What virus component determines antiserum resistance?
We have found four PBCV-1 serotypes and discovered that the
antisera react primarily with oligosaccharide(s) attached to the
major capsid protein plus two minor glycoproteins. More importantly, in contrast to normal virus protein glycosylation,
the virus rather than the host dictates glycosylation specificity.
Materials And Methods
Culture Conditions. The procedures for producing, purifying, and “plaquing” the viruses and the growth of the host
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protein was dried, resuspended in dissociation buffer, and electrophoresed on preparative polyacrylamide gels as described
above. After electrophoresis the major capsid protein was visualized by soaking the gel in 4 M sodium acetate (13). The major
capsid protein region was excised with a razor blade and cut into
small blocks, and protein was electroeluted and concentrated using an ISCO electrophoretic concentrator. The concentrator contained 10 mM NH4HCO3/0.1% SDS in the sample cup and 50
mM NH4HCO3/0.1% SDS in the buffer chambers. After elution,
protein was precipitated with 5 vol of acetone.
Deglycosylation. The major capsid proteins were deglycosylated with trifluoromethanesulfonic acid (TFMSA) by a
modification of the procedure of Edge et al. (14). Virus or purified major capsid proteins were suspended in 50 μl of TFMSA
and 25 μl of anisole and incubated on ice for 1-3 hr. The reaction was stopped by adding 125 μl of N-ethylmorpholine (15).
Protein was recovered by acetone precipitation and immediately analyzed on SDS/polyacrylamide gels.
Sugar Analysis. Equal volumes of 65°C solubilized viral
proteins (see above) were mixed with equal volumes of 4 M
trifluoroacetic acid and hydrolyzed for 4 hr at 100°C. The samples were cooled and the acid was evaporated. The samples
were suspended in deionized water and passed through an
OnGuard A cartridge (Dionex). Monosaccharides were bound
to a Dionex Carbopac PA1 anion-exchange column and eluted
for 35 min with isocratic 2.5 mM NaOH (16) by procedures
recommended by Dionex. Peaks were integrated and plotted
on a Dionex 4400 integrater. The internal standard was 2-deoxyglucose. Retention times and peak areas were compared to
standards including fucose, galactosamine, galactose, glucosamine, glucose, xylose, arabinose, rhamnose, and mannose.
Other Procedures. Nitrocellulose sheets containing virus
proteins were mildly oxidized with periodic acid as described
by Woodward et al. (17). Polyclonal antiserum to the viruses
was raised against purified viruses as described (18). DNA
was isolated from the purified viruses as described (19) and
treated with restriction endonucleases according to suppliers’
protocols. DNA was sequenced in both directions by the procedure of Sanger et al. (20), as modified by Tabor and Richardson (21), using a Sequenase (Version 2.0) kit from United
States Biochemical.
Results
Isolation of PBCV-1 Serotypes. We have isolated (7) a mutant of PBCV-1, EPA-1, that was resistant to PBCV-1 polyclonal antiserum. Polyclonal antiserum prepared against EPA1 inhibited EPA-1 infection (dilution of 1:1000) but not PBCV-1
infection even at high antiserum concentrations (7). Additional spontaneously derived PBCV-1 serotypes were selected
with polyclonal antisera prepared against either PBCV-1 or serotypes derived from PBCV-1. Four serologically distinct mutant classes (summarized in Table 1) of PBCV-1 were obtained:
P91; P31 and EPA-1; P41 and E11; and P100. Virus E11 arose
from EPA-1 and virus P100 arose from P31; presumably, these
two viruses contain two independent mutations. Each of these
viruses was stable and polyclonal antiserum made to one of
the serotypes completely inhibited infection by members of
the same serotype (at a dilution of 1:1000) but had no effect at
a 1:4 dilution on the other serotypes.
The polyclonal antisera inhibit homologous virus infection
by agglutination. Antisera treated with papain, which produces monovalent Fab fragments (22), did not inhibit homologous virus infection. However, adding goat anti-rabbit IgG to
Fab-treated virus inhibited virus infection.
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Table 1. Virus PBCV-1 serotypes
Antiserum agglutination
Virus

Source

PBCV-1

P91

EPA-1

P41

P100

PBCV-1
P91
EPA-1
P31
P41
E11
P100

—
PBCV-1
PBCV-1
PBCV-1
PBCV-1
EPA-1
P31

Yes
No
No
No
No
No
No

No
Yes
No
No
No
No
No

No
No
Yes
Yes
No
No
No

No
No
No
No
Yes
Yes
No

No
No
No
No
No
No
Yes

Polyclonal antiserum was prepared against PBCV-1, P91, EPA-1, P41,
and P100 viruses. Yes = a 1:1000 dilution of the indicated antiserum
indicated agglutinated the virus; No = a 1:4 dilution of the antiserum
indicated did not agglutinate the virus.

Virus DNA. DNA from each of the viruses was digested
with several DNA restriction endonucleases and analyzed on
agarose gels. Identical restriction fragments were observed with
DNA from PBCV-1, P91, P31, P41, and P100 with each of the restriction endonucleases. A single common BamHI fragment and
a single Hha I fragment (Figure 1) were altered in DNA from
EPA-1 and E11. The altered BamHI fragment (B8a) is located at
positions 55-66 on the physical map of PBCV-1 (6). This suggests
that EPA-1 arose from a deletion and that P91, P31, P41, and
P100 arose from either point mutations or very small deletions
in separate PBCV-1 genes. E11 likely arose from a point mutation in EPA-1, possibly in the same gene that produced P41.
Protein Patterns of the PBCV-1 Serotypes. Each of the viruses was heated either to 65°C for 1 hr or 100°C for 5 min
in dissociation buffer and the proteins were electrophoresed
on SDS/polyacrylamide gels. The PBCV-1 major capsid protein (Vp54), which makes up ≈40% of the total virus protein,
migrates as a dimer when heated to 65°C and as a monomer
when heated to 100°C (4, 23). As shown in Figure 2A, both the
dimer and monomer forms of the major capsid protein of each

Figure 1. Digestion patterns of PBCV-1 (lane 1), P91 (lane 2), EPA-1
(lane 3), P31 (lane 4), P41 (lane 5), E11 (lane 6), and P100 (lane 7) viral
DNA. The DNAs were digested with BamHI (A) or Hha I (B). A single
BamHI fragment and a single Hha I fragment (arrow) were altered in
the DNAs from EPA-1 and E11.
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Figure 2. (A) SDS/PAGE of the major capsid protein from PBCV-1, P91, EPA-1, P31, P41, E11, and P100 viruses. The samples were heated to 65°C
for 1 hr (dimer), 100°C for 5 min (monomer), or deglycosylated with TFMSA prior to electrophoresis. (B) Immunoblot of the major capsid protein
from PBCV-1, P91, EPA-1, P31, P41, E11, and P100. The blots were treated with antiserum (Ab) against PBCV-1, P91, EPA-1, P41, or P100 as indicated. Note: the major capsid proteins reacted primarily with homologous antiserum. (C) Migration of [3H] galactose-labeled glycoproteins from
PBCV-1, P91, P31, P41, and P100 viruses. The samples were heated at 100°C for 5 min prior to electrophoresis. Note: the virus mutations that affect
the migration of the major capsid protein also affect the migration of the two minor viral glycoproteins. Molecular masses in kDa are shown.

mutant migrated faster than the major capsid protein of its
parent. Furthermore, the major capsid proteins from the serotypes migrated differently from one another, whereas the major capsid protein from viruses in the same serotypes migrated
at identical rates. The viruses PBCV-1, P91, EPA-1 and P31, P41
and E11, and P100 are arranged in Figure 2A by decreasing size
of the major capsid protein. The virus mutations that affected
the migration of the major capsid protein also affected the migration of the other two viral glycoproteins (Figure 2C). Like
the major capsid protein, these two glycoproteins, each being
1–2% of the total virus protein, migrated faster than the parental glycoproteins. Other proteins were unaffected. The change
in the glycoproteins in the serotypes was consistent with the
glycoprotein determining serological specificity of the viruses.
This possibility was supported by Western blot analysis. The
virus major capsid proteins (Figure 2B) and the other two minor
virus glycoproteins reacted strongly only with homologous antiserum. Each antiserum also reacted, but to a much lesser extent, with other virus proteins, presumably reflecting epitopes
exposed by disruption of virus particles during immunization.
None of the virus antisera reacted with host chlorella proteins.
The Primary Epitope Is Oligosaccharide(s). The epitope(s)
responsible for the serological specificity could be either the
carbohydrate or polypeptide portion of the major capsid protein. The major capsid proteins from all the viruses comigrated
with an apparent molecular mass of 49 kDa in SDS/polyacrylamide gels after deglycosylation with TFMSA (Figure 2A). The
value of 49 kDa agrees with the predicted molecular mass of
48.2 kDa for the PBCV-1 major capsid protein derived from sequencing its gene (23). The apparent identity of the deglycosylated major capsid proteins from all the virus serotypes indicates that the protein size differences reflect differences in the
carbohydrate moieties. Three experiments confirmed this conclusion. (i) Deglycosylation abolished the specific reaction of
the major capsid proteins with homologous antiserum. (ii) Periodic acid treatment of virus proteins after transfer to nitrocellulose, which destroys carbohydrate epitopes of glycoproteins
(17), reduced the reaction of the antisera with the major capsid
proteins, but not with the other virus proteins. (iii) The ratios
of six and/or seven sugars (fucose, galactose, glucose, xylose,

mannose, and arabinose and/or rhamnose) associated with the
viral glycoproteins of PBCV-1 and the mutants varied in a predictable manner that was related to their serotypes and the apparent size of the glycoproteins (Table 2). Thus we conclude
that the oligosaccharide(s) attached to the major capsid proteins determines the serological differences among the viruses.
Sequence ofthe Major Capsid Protein Gene. The major capsid protein gene from the parent virus PBCV-1 was recently isolated and sequenced; the Vp54 gene is located at positions 209–211 on the PBCV-1 physical map (23). An amino
acid change(s) in the major capsid protein could alter a glycosylation site(s) in the protein leading to oligosaccharide(s) differences among the PBCV-1 serotypes. To examine this possibility, we cloned and sequenced the major capsid protein gene
from viruses EPA-1 and P100. The base sequence and, hence,
the predicted amino acid sequence for the major capsid proteins from both mutants was identical to that of PBCV-1.
Discussion
Four spontaneously derived serologically distinct classes
of mutants of the chlorella virus PBCV-1 were isolated using polyclonal antiserum made against either PBCV-1 or the
Table 2. Sugar composition of the glycoproteins from PBCV-1 
serotypes
Relative sugar content
Sugar
Fucose
Ara/Rham
Galactose
Glucose
Xylose
Mannose

PBCV-1

P91

EPA-1

P31

P41

E11

P100

0.69
1.57
1.02
1.00
1.58
1.02

0.73
1.24
0.97
1.00
1.47
0.70

0.88
0.64
1.02
1.00
1.59
0.14

0.81
0.65
1.03
1.00
1.57
0.17

0.78
0.65
0.99
1.00
0.88
0.24

0.83
0.65
0.97
1.00
0.77
0.15

0.61
0.19
0.91
1.00
0.60
0.12

Values are normalized to that of glucose. Note: fucose and galactose
also do not change. The mutants are arranged so that the major capsid
protein decreases in size from PBCV-1 to P100. Viruses EPA-1 and P31
and viruses P41 and E11 are serologically similar even though they are
separate isolates. Viruses P91, EPA-1, P31, and P41 are derived from
PBCV-1; virus E11 is derived from EPA-1; and virus P100 is from P31.
Ara/Rham = arabinose/rhamnose.
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Figure 3. Proposed model for the structure of the oligosaccharide moieties attached to the viral major capsid protein. In this model, sugars
B-E may represent monosaccharides, oligosaccharides, or different
types of linkages. Enzymes I-IV are responsible for the transfer of sugars B-E to preexisting substrates. Presumably, the sugars can only be
added in the order presented so that, e.g., a defect in enzyme I prevents the addition of any sugars onto sugar A. PBCV-1 serotypes that
could be missing an enzyme activity are listed on the left.

serotypes. Virus major capsid protein and two minor viral glycoproteins (apparent molecular masses of 280 and 270
kDa from PBCV-1), from the serotypes migrated in a distinctive but predictable fashion on SDS/polyacrylamide gels (Figure 2C), whereas the remaining viral proteins comigrated.
The polyclonal antisera recognize oligosaccharide epitopes
on the major capsid protein. The two other viral glycoproteins share these epitopes and are affected in parallel by antiserum-resistance mutations. By these criteria the oligosaccharides of the three glycoproteins are indistinguishable.
Glycoproteins are important structural components of
many viruses (24). Usually the carbohydrate moieties of virus glycoproteins are added in the rough endoplasmic reticulum and Golgi by host-encoded glycosyltransferases (24). Virus glycoproteins are then transported to the cell membrane
and viruses acquire their glycoprotein(s) by budding through
the host membrane as they are released from the cell. Consequently, changes in the glycan portion of virus glycoproteins
can occur (i) by varying the host [e.g., herpesvirus (25, 26) and
influenza virus (27, 28)] or (ii) by altering an amino acid sequence to create or destroy a glycosylation site [e.g., vesicular stomatitis virus (29)]. However, neither of these mechanisms explain the altered glycan(s) in the major capsid protein
of PBCV-1: (i) All viruses are grown in the same host, and (ii)
the predicted amino acid sequences of the major capsid protein from PBCV-1 and two of its serotypes, EPA-1 and P100,
are identical. Furthermore, the PBCV-1 major capsid protein
and the other two virus glycoproteins are added to the virus
inside the cell since intact infectious PBCV-1 particles accumulate within the cell prior to virus release (1).
The pattern of antiserum-resistant mutants suggests that
PBCV-1 influences at least four steps of a common glycosylation pathway. Because mutant glycoproteins migrate faster
on SDS/polyacrylamide gels than those of the parents, it is unlikely that the mutation affects a glycosidase cleavage pathway
since this would produce a larger oligosaccharide. Three other
observations are consistent with the glycosylation hypothesis:
(i) Each of the four virus serotypes appear to arise from separate single mutations in the PBCV-1 genome. Although more
sophisticated genetic analyses are required to determine mutation frequencies, the serotypic variants are present at ≈1 per
106 virus particles. This number is consistent with a single mu-
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tation. (ii) The major capsid protein of PBCV-1 and the serotypes contains six and/or seven sugars (fucose, galactose, glucose, xylose, mannose, and arabinose and/or rhamnose) that
vary in a predictable manner that is related to their serotype
and the migration of the major capsid protein (Table 2). (iii)
The viral antisera did not react with host proteins.
A model consistent with the data is presented in Figure
3. The PBCV-1 major capsid protein has one or more glycan
components containing sugars in sequential order: sugar A–
sugar B–sugar C–sugar D–sugar E. Sugar A is attached to the
amino acid and the terminal sugar E serves as the PBCV-1 epitope. Virus P91 contains a mutation that prevents the addition
of sugar E; consequently, terminal sugar D serves as the P91
epitope. The other virus serotypes result from mutations that
eliminate additional terminal sugars; in each case the terminal
sugar serves as the epitope. Two variations of the model are
also consistent with the data. (i) The linkage of the terminal
sugar differs with each serotype or (ii) the sugars represented
as A, B, C, D, and E consist of more than one sugar.
This simple testable model explains the specificity of each
antiserum, the different carbohydrate contents of the major
capsid proteins of each serotype, and the mobility differences
of the major capsid proteins on SDS/polyacrylamide gels. The
model also predicts that the gene for each enzyme can be independently mutated and that genetic crosses between appropriate serotypes should produce wild-type viruses. It will also
be important to determine the intracellular location of PBCV1 protein glycosylation. The proteins could be glycosylated
via the conventional rough endoplasmic reticulum and Golgi
pathway, possibly using virus-encoded glycosyltransferases.
If so, the virus glycoproteins need a signal for targeting them
to the virus cytoplasmic assembly centers. Alternatively, viral
glycosylation could be independent of the traditional rough
endoplasmic reticulum and Golgi system. In this regard, evidence is accumulating for nuclear and cytoplasmic glycosylation of some cell proteins (for review, see reference 30).
In summary, chlorella virus PBCV-1 has an interesting and
apparently unusual method for glycosylating its glycoproteins.
Regardless of whether PBCV-1 encodes its own glycosylating
enzymes or somehow manipulates host enzymes, the mechanism adds still another function encoded by PBCV-1. The chlorella viruses are unusual in that they code for DNA site-specific
(restriction) endonucleases and DNA methyltransferases (6).
We thank Dwight Burbank for technical assistance, Russ Meints
and Mike Graves for advice on cloning the major capsid protein gene
from the PBCV-1 mutants, Ken Nickerson for advice on the sugar
analyses, and Peter Albersheim and Gary Hart for helpful discussions. This investigation was supported, in part, by Public Health Service Grant GM-32441 from the National Institute of General Medical
Sciences. This manuscript is Journal Series No. 10152, Agricultural Research Division, University of Nebraska.
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